A review on vaccination against protozoa and arthropods of veterinary importance.
The recent advances in immunology and biotechnology have stimulated much research on the control of parasitic diseases through vaccination. This is a review of the state of the art regarding important protozoan and arthropod veterinary parasites. A live oocyst vaccine for avian coccidiosis is still in use but much work has been done on the identification, cloning, and assay of protective antigens. The sporozoites of Eimeria tenella have been the preferred subject and at least four recombinant antigens have already been tested with partial success. Premunization against babesiosis is still widely used in Latin America as is a live vaccine with attenuated parasites in Australia. At least three Babesia bovis and three Babesia bigemina antigens that generate partial protection have been produced as recombinant proteins. A vaccine against canine babesiosis is being commercialized in France. Infection-treatment is still used to vaccinate against Theileria parva and a schizont vaccine against Theileria annulata. Recombinant sporozoite antigens have been assayed with partial success against both species but the identification and administration of protective schizont antigens, regarded as the most important, still requires considerable work. The immunological control of African trypanosomoses is still impaired by the antigenic variation that the parasites experience during the infection. Although some possibilities exist, most specialists are pessimistic about the promise of developing a vaccine in the near future. Control of Boophilus ticks with an occult tick intestine recombinant antigen seems to have potential in inhibiting reproduction of the tick but salivary antigens appear to be more effective at inhibiting feeding and pathogen transmission. Vaccination with a Hypoderma protein, recently cloned, has induced 90% protection against subsequent infestations. It is very likely that effective vaccines against veterinary parasites will become available in the near future.